Infliximab (anti-TNF-␣ monoclonal antibody) induces remission in 30-40% of Crohn's disease patients. Treatment response is a stable trait. Two cohorts from independent, prospective clinical trials of infliximab in Crohn's disease were studied. Hypotheses were generated in an exploratory cohort (n ϭ 90) and then tested in a confirmatory cohort (n ϭ 444), using a statistical design, which is stable against type 1 and type 2 errors. In the exploratory cohort, the mutant 196Arg allele of TNFR-II (exon 6 polymorphism) and a novel silent polymorphism in exon 2 of TNFR-II were associated with lack of response to infliximab (83.3% in homozygote mutant 196 Arg patients vs 36.9% in heterozygotes and wild-type homozygotes (P = 0.036) and 85.7% in homozygote mutant exon 2 patients vs 36.1% (P ϭ 0.01), respectively). None of the homozygote mutant individuals (0/6) achieved clinical remission, whereas the remission rate was 35.7% (30/84) in wild-type homozygotes and heterozygotes. In the large second cohort, the observed genotype-phenotype associations were not replicated. Other polymorphisms (TNF-␣ promoter Ϫ238, Ϫ308, Ϫ376, Ϫ857, Ϫ1031, TNF-R-I Ϫ609, +36 (exon 1), TNF-R-II 1663, 1690 (3Ј-UTR)) were not associated with treatment response in both cohorts (P Ͼ 0.5). None of the polymorphisms was associated with refractory Crohn's disease itself when compared to healthy controls. In a two-cohort study, a series of polymorphisms in the TNF, the TNF-R-I and in the TNF-R-II genes could be thoroughly excluded as pharmacogenetic markers for a treatment response to infliximab and as etiologic factors for Crohn's disease, respectively. The discrepancy between the two cohorts observed for the TNF-R-II exon 6 and exon 2 polymorphism may point to a weak effect on treatment response but also serves to illustrate the need for a sequential exploratory/confirmatory design in pharmacogenetic studies.
INTRODUCTION
Drugs (eg monoclonal antibodies), that specifically target single molecules in disease pathophysiology can be very effective in subgroups of patients, but are often of limited utility in other parts of the patient population. Clinical markers for the prediction of response are often unknown. Therefore, the use of genetic markers is an attractive concept. The statistical validity of results from many pharmacogenetic studies is easily compromised by the secondary nature of their design as clinical cohorts built up for efficacy trials are used in a post-hoc analysis.
Pharmacogenetic studies often result in positive findings, which are made in small cohorts. This leads to a high vulnerability for type 1 errors (false positive findings) and a lack of power for an effective exclusion of genetic variants. In addition, pharmacogenetic association studies cannot use more stable, family-based designs that have been developed for the exploration of polygenetic conditions in order to reduce false positive findings (as for instance the 'transmission disequilibrium test, TDT' 1,2 ), because relatives are not recruited in efficacy-driven clinical trials. We therefore propose to use a two-cohort approach in the investigation of pharmacogenetic cohorts that allows the separation of hypothesis generation and verification.
Crohn's disease is characterized by chronic relapsing intestinal inflammation. Glucocorticoids are an effective short-term treatment of acute relapse in most patients. 3, 4 However, long-term maintenance of remission is difficult in many patients. It is estimated that at least 50% of patients develop steroid-refractory or -dependent disease. An increased production of pro-inflammatory cytokines, including TNF-␣ in the intestinal mucosa is pivotal for the development of inflammatory relapses as well as chronic inflammatory activity. 5, 6 Monoclonal antibodies binding specifically to TNF-␣ (infliximab, CDP571) have been shown to be an effective treatment for therapy-refractory Crohn's disease. 7, 8 A single infusion of infliximab results in a remission rate of approximately 30-40% in Crohn's disease, without any statistically significant differences observed between different dose groups (5, 10 and 20 mg kg Ϫ1 bodyweight). 7 Additional compounds from the same class of substances (ie CDP571, 8 
D2E7
, 9 CDP 870 and TNF binding protein-1) are under current clinical development.
The selective response to intravenous application of infliximab, with a sustained benefit in 30-40% of patients, the potential for severe, although rare side effects 10, 11 and the high price of the therapy suggest the exploration of predictors of therapeutic efficacy. Since non-responsiveness to medication seems to be a stable trait, even after repeated dosing, 7, 12 a pharmacogenetic study of therapeutic efficacy appears suitable. Infliximab exerts its influence through the specific binding and removal of TNF-␣. The TNF/TNF receptor system appears to be a prime candidate for a pharmacogenetic exploration. Infliximab can bind receptor-attached or membrane-expressed TNF-␣, which may lead to the elimination of activated immune cells either by complement activation or induction of apoptosis. 13 Conformational variants of the TNF receptors I and II may therefore be important. TNF receptor I (CD120a) is a 55/60 kD (455 amino acid residues) transmembrane glycoprotein expressed on most nucleated mammalian cells. 14 The gene coding for TNF receptor I comprises 10 exons and is located on chromosome 12p13. 15, 16 TNF receptor II (CD120b) is a 75/80 kD (461 amino acid residues) transmembrane glycoprotein expressed primarily by cells of the hematopoietic lineage and controls thymocyte and peripheral T-cell proliferation, natural killer cell and neutrophil activation. [17] [18] [19] The gene coding for TNF receptor II comprises 10 exons and is located on chromosome 1p36. 20, 21 The TNF-␣ gene is located on chromosome 6p21.3. The protein itself is not polymorphic in Caucasians as evidenced by previous population studies.
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MATERIALS AND METHODS

Prospective Clinical Trials
Patients from two prospective, multicenter clinical trials were investigated. The first trial (39 German centres 12 ) was specifically set up to evaluate molecular and clinical predictors of a therapeutic response to infliximab (5 Ϫ1 bodyweight) was administered to all patients with chronic active Crohn's disease at the beginning of the study. Patients were later randomized to a placebo controlled re-infusion protocol (which was not part of our assessment). The clinical protocols and the genetic test procedures received prior approval by the ethics committees/institutional review boards of all participating institutions. All patients gave written informed consent to the study and to the pharmacogenetic substudy before treatment and genotyping, respectively.
Patient Selection
Inclusion criteria were similar to those used in previously published studies performed to establish the clinical efficacy of infliximab in Crohn's disease. 7, 24 For the first multicenter trial, patients were required to have chronic active (CDAI 220-450) Crohn's disease in the ileum and/or colon (Ͼ 6 months since diagnosis) with or without fistulae. Previous unsuccessful therapy had to include at least one of the following: (i) glucocorticoids (Ͼ 10 mg day Ϫ1 for at least 3 months with changes Ͻ 20 mg (in the average daily dose) during the last 4 weeks and Ͻ 5 mg (average daily dose) during the last 2 weeks); (ii) azathioprine (Ͼ 3 months, у2 mg kg Ϫ1 bodyweight and day); (iii) 6-MP (Ͼ 3 months, у1 mg kg Ϫ1 bodyweight and day); (iv) methotrexate (Ͼ 3 months). Age limits were 18-65 years.
Exclusion criteria were pregnancy, severe other disease (including irritable bowel syndrome, gastrointestinal infections), the presence of an ileo or colostomy, a foreseeable need for surgery, a documented or suspected fixed stenosis, and prior treatment with biological substances directed against TNF. Other investigational drugs were not allowed within 30 days. Further laboratory exclusion parameters were leucocyte counts Ͻ 3.5 ϫ 10 9 liter
Ϫ1
, hemoglobin Ͻ 85 g liter Ϫ1 , neutrophil counts Ͻ 1.5 ϫ 10 9 liter Ϫ1 and/or thrombocyte counts Ͻ 100 ϫ 10 9 liter
A total of 154 patients were screened. Of those 132 patients who matched the inclusion and exclusion criteria, 90 (57 women and 33 men) volunteered to take part in the pharmacogenetic sub-study. As requested by the ethics com-mittee, those patients not willing to donate DNA received free, open label treatment with infliximab and were clinically followed, also. All patients received infliximab in a dose of 5 mg kg Ϫ1 bodyweight at week 0, with repetitions at weeks 2 and 6 for those patients having fistulae (44 of 90) . Primary definition of therapeutic response was a drop of the CDAI by at least 70 points 4 weeks after the first infusion. Remission, as a secondary end point, was defined as a CDAI value smaller than 150 points at week 4. 3, 4 The inclusion criterion for the second randomised, placebo-controlled trial was chronic active Crohn's disease (CDAI 220-400) in the ileum and/or colon (Ͼ 3 months since diagnosis by radiography or endoscopy) without draining fistulae. Concomitant medications such as aminosalicylates, corticosteroids, azathioprine, 6-mercaptopurine, mycophenolate mofetil and methotrexate were allowed at a stable dose before and during the trial. Crohn's disease-specific antibiotics had to be discontinued at least 2 weeks prior to pre-screening. Minimum age was 18 years. Exclusion criteria were pregnancy, severe other disease (including irritable bowel syndrome and gastrointestinal infections), presence of draining enterocutaneous fistulae or any internal fistulae, a foreseeable need for surgery, a documented or suspected fixed stenosis and prior treatment with anti-TNF. Other investigational drugs were not allowed within 30 days. Further laboratory exclusion parameters were leucocyte counts Ͻ 3.5 ϫ 10 9 liter
, hemoglobin Ͻ 85 g liter Ϫ1 , neutrophil counts Ͻ 1.5 ϫ 10 9 liter Ϫ1 and/or thrombocyte counts Ͻ 100 ϫ 10 9 liter Ϫ1 . Of the 580 patients enrolled into the clinical trial, 444 patients agreed to participate in genotyping. All patients received infliximab in a dose of 5 mg kg Ϫ1 bodyweight at week 0. Definition of therapeutic response was a drop of the CDAI by at least 70 points 2 weeks after the first infusion. Remission, as a secondary end point, was defined as a CDAI value smaller than 150 points. 3, 4 Controls were healthy North-European blood donors from the Kiel region.
Sequencing
DNA was extracted by standard techniques (guanidinedetergent lysis) from the EDTA blood of the 534 patients (90 from the first and 444 from the second trial) and 370 sexand age-matched healthy controls and dispensed on 96-well plates (20 ng well
Ϫ1
). The complete coding sequence, exon-flanking intronic sequences and the promoters of the TNF receptor I and II genes were investigated for polymorphisms using direct sequencing in 45 individuals of the study population (10 patients and 35 controls). The primers were designed using Primer Express (PE Biosystems, Foster City, CA, USA). Primers used for sequencing are posted on the Journal's website and under www.mucosa.de/labtools/sequencingFprimers. The PCR amplification products were sequenced using the PCR primers according to Applied Biosystem's (ABI, Foster City, CA, USA) 'Big Dye Terminator' protocol and analysed on an ABI 310 or an ABI 3700 automated sequencer.
www.nature.com/tpj Genotyping Eleven SNPs were genotyped using allelic discrimination by TaqMan (ABI 7700 PE Biosystems). Five polymorphisms in the promoter of the TNF-␣ gene (at nucleotide positions Ϫ238, Ϫ308, Ϫ376, Ϫ857 and Ϫ1031); two SNPs in the TNF receptor I gene (one in the promoter at position Ϫ609 and one in exon 1 (silent mutation at nucleotide position 36, Pro12Pro)) and four SNPs in the TNF receptor II gene (a silent mutation in exon 2 at nucleotide position 168, Lys56-Lys (AAA-AAG), a change of a second codon position in exon 6 at nucleotide position 587, Met196Arg (ATG-AGG), (nucleotide positions refer to the transcription start site) and two mutations in exon 10 in the 3Ј untranslated region at nucleotide position 1663 and 1690 (nucleotide position refers to Genbank M32315)) were investigated. [25] [26] [27] [28] [29] [30] Genotypes were assigned without knowledge of individual treatment response. Primers and probes (Table 1) were designed with Primer Express and synthesized through Eurogentec (Liege, Belgium) or Applied Biosystems (Weiterstadt, Germany), respectively. The amplification conditions (ABI 9700) involved two pre-PCR steps of 2 min at 50°C and 10 min at 95°C, followed by a variable number of cycles including a denaturation step at 95°C for 15 s and an annealing step of 1 min in a final volume of 10 l ( Table 2 ). The genotypes obtained by TaqMan were confirmed by direct sequencing in 45 individuals, obtaining identical results in all cases.
Statistical Analysis
All samples were re-coded and processed blind to clinical response. In order to reduce the amount of multiple testing, it was decided beforehand to investigate coding polymorphisms in the TNF and the TNF-receptor genes under the primary hypothesis. Non-coding polymorphisms were investigated under a secondary hypothesis.
The software package SPSS was used for statistical data analysis. 31 The significance of difference between medians of different cases examined was evaluated by a modified Kruskal-Wallis test. For the evaluation of the response rates, a polynomial 2 test was used. The influence of the infusion schema in the first study was evaluated by logistic regression. Pairwise linkage disequilibrium between markers and haplotypes were estimated with the EH program (by Jurg Ott, from http://linkage.rockefeller.edu/ott/eh.htm).
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RESULTS
Clinical Response Rate in the Two Clinical Trials
The investigations were performed in cohorts from two independent, prospective, multicenter trials of infliximab (n ϭ 90, n ϭ 444) in chronic active Crohn's disease patients. Hypotheses generated in the first population under exploratory conditions were verified in the second cohort. The first cohort (n ϭ 90) was raised specifically for the exploration of therapeutic predictors.
In the exploratory cohort, we observed 60% clinical responders at week 4 (reduction of Crohn's disease activity index of at least 70 points) and a remission rate (Crohn's disease activity index Ͻ150 points) of 33%, without signifi- 
cant differences between infusion schemas (P ϭ 0.262). The median drop in the Crohn's disease activity index was 110 points. In the confirmatory cohort (444 patients), the response rate was 62% (reduction of CDAI of at least 70 points) and the remission rate was 28%. This response pattern is in agreement with published controlled trials of infliximab in Crohn's disease .
Polymorphism Detection in the TNF Receptors II and I
In the TNF-receptor II, direct sequencing of 45 individuals confirmed the known coding T/G polymorphism at nucleotide 587 (from the transcription start site, exon 6 (E6)), which induces an amino acid change (Met196Arg). In addition, known polymorphisms at positions 1663, 1668
The Pharmacogenomics Journal and 1690 in the 3Ј untranslated region (numbering according to Genbank sequence M32315) were detected. Nucleotide position 1668 showed a low frequency polymorphism with only two heterozygotes out of 45 tested. Further polymorphisms suggested by database searches (GenBank) were not present in our sequencing sample (exon 4, exon 9, at position Ϫ1413 and Ϫ1120 in the promoter and at position 2007 in the 3Ј untranslated region). A novel polymorphism (an A/G transition at position 168 from the transcription start site, which represents a silent mutation in exon 2 (Lys56Lys)) was identified. An analysis of pair-wise linkage disequilibrium (LD) between the SNPs in the TNF receptor II showed strong LD between the TNF-receptor-II exon 2 and TNF-receptor-II exon 6 polymorphisms ( 2 ϭ 222, P Ͻ 0.001), but no LD between the TNF-receptor-II exon 6 polymorphism and polymorphisms in the 3Ј untranslated region ( 2 Ͻ 1, P Ͼ 0.50). Through direct sequencing of the TNF-receptor I gene, we confirmed five known polymorphisms: one in the promoter at nucleotide position Ϫ609, one in exon 1 at nucleotide position +36 (Pro12Pro) (both from the transcription start site), two in intron 4 (at nucleotide positions 147 and 186 from the end of exon 4) and one in intron 6 (at nucleotide position 10 from the end of exon 6). Further polymorphisms, which were suggested by the GenBank search, were not detected in our sample (promoter positions Ϫ580 and Ϫ383, in intron 2, intron 7 and an 'A' deletion in intron 8).
A search for novel polymorphisms in the TNF-gene was not conducted since this gene has been extensively characterised in different populations through previously published work.
Analysis of Association Between Therapeutic Response and Polymorphisms in the TNF-alpha Gene and its
Receptors (Exploratory Cohort, n ϭ 90) Our primary hypothesis was focussed on coding polymorphisms. Only the exon 6 polymorphism in the TNF-receptor II gene causes an amino acid exchange (Met196Arg). Homozygosity of the mutant allele (ie 196Arg/196Arg) appeared to be associated with a lack of response to infliximab. Response (drop of CDAI Ͼ 70 points) was seen in 36 out of 61 wildtype homozygotes, 17 out of 23 heterozygotes but only one out of six homozygote mutants (P ϭ 0.049 for homozygous mutant vs homozygous wild-type, P ϭ 0.011 vs heterozygous, P ϭ 0.036 for homozygous mutant vs both other genotypes combined). The comparison between heterozygotes (196Arg/196Met) and homozygotes for the wildtype allele (196Met/196Met) was not statistically significant (P ϭ 0.213).
A similar trend was seen with respect to remission rates: a CDAI less than 150 points was observed in none of the six homozygote mutants as compared to 30/84 (36%) in heterozygotes (11/23) and wild-type homozygotes (19/61) combined (P ϭ 0.073).
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The median drop in the Crohn's disease activity index was 108 points for wild-type homozygotes and 123 points for heterozygotes (P ϭ 0.46). In contrast, individuals homozygote for the mutant allele (six individuals) showed a median drop in the Crohn's disease activity index of 61.5 (P ϭ 0.091 for comparison between homozygote mutants and the two other genotypes combined).
The newly detected silent TNF receptor II exon 2 polymorphism, which is in strong linkage disequilibrium with the coding polymorphism in exon 6, was also significantly associated with a lack of response to treatment with infliximab (non-response in six of seven homozygote mutants as compared to 30 of 83 heterozygotes or wild-type homozygotes, P ϭ 0.01). None of the other, silent polymorphisms in the TNF receptor I and II genes or in the TNF-␣ gene promoter were associated with response to infliximab (P Ͼ 0.50 for all polymorphisms tested).
All 16 haplotypes that are theoretically possible for the four polymorphisms typed in the TNF receptor II gene were detected in the population. Table 3 details the distribution of the different haplotypes. The combination of haplotypes (eg 1-1-1-2 and 2-2-1-1) did not yield any additional significant finding over and above those observed for single markers.
Analysis of Association Between Therapeutic Response and Polymorphisms in the TNF-alpha Gene and its Receptors in the Confirmatory Cohort (n ϭ 444)
In order to verify the hypotheses obtained in the exploratory cohort, we analysed the same set of SNPs in the second trial cohort. The 196Met/196Arg polymorphism in exon 6 of the TNF receptor II (TNF-R-II E6) was first analysed separately under our primary hypothesis. Non-response was observed in 5/20 (25%) homozygote mutants, 38/118 (32%) heterozygotes and 40% wild-type homozygous patients. Remission rates were 29%, 29% and 26%, respectively (PϾ0.5). The allele frequencies for the TNF receptor II exon 6 polymorphism as determined in 370 North European healthy controls (196Arg: 18.6%, 196Met: 81.4%), in the exploratory patient sample (196Arg: 19.5%, 196Met: 80.5%) 
total) (Exon 2 G/A) (Exon 6 G/T) (3ЈUTR A/G) (3ЈUTR T/C)
n ϭ 370 n ϭ 531
and in the confirmatory patient sample (196Arg: 19.9%, 196Met: 80.1%) were not significantly different and were similar to those previously obtained in a UK control population. 30 As expected, the newly detected TNF-R-II-E2 SNP was again found to be in strong linkage disequilibrium with the coding SNP in exon 6 (P Ͻ 0.001). No association with therapeutic response to infliximab was seen in the confirmatory cohort. The haplotype analysis of TNF-R-II polymorphisms also failed to show any significant differences between responders and non-responders (and remissions/non-remissions, respectively).
We confirmed the exploratory hypothesis that none of the other polymorphisms in the TNF receptor I and II genes or in the TNF-␣ gene promoter were associated with response to infliximab (P Ͼ 0.50, data not shown).
Polymorphism in the TNF-alpha, TNF-Receptor I and II as Susceptibility Factors for Crohn's Disease in General
We compared the allele and genotype frequencies of the 534 Crohn's disease patients (both trials combined) with those of 370 unrelated healthy controls. No significant differences in allele or genotype frequency were observed between the two populations (P Ͼ 0.5). Therefore, none of the tested polymorphisms appears to influence the risk for Crohn's disease (Table 4) . Haplotype analysis also failed to reveal any association between Crohn's disease and polymorphisms in the TNF receptor II, TNF receptor I or TNF genes, respectively (Table 3) .
DISCUSSION
Infliximab is a potent new therapy for refractory Crohn's disease. Some patients demonstrate a sustained benefit while others respond significantly less well. 7, 12, 33, 34 Therapeutic response to infliximab is a stable trait. 7, 12, 33 Since infliximab binds specifically to TNF-␣, we investigated the influence of
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The two-cohort design used in this study addressed our main concern that type 1 statistical errors may affect the results of pharmacogenetic association studies but, at the same time, maximized the power to detect a polymorphism associated with response to infliximab. Assuming a population frequency of 20% for a genotype predisposing to nonresponse, and a relative risk of 2, the power of this design is 97% to detect an effect in at least one of the two studies at an alpha level of 0.05 (the power is 90% for a genotype frequency of 10%). This means that a polymorphism can be ruled out from representing a strong causative or associated markers for treatment response, respectively, if no association is detected with Pр0.05 in at least one of the studies.
Under the primary hypothesis, only coding polymorphisms were investigated; and only one such polymorphism was found (TNF-receptor II-exon 6, 196Met/Arg). A statistically significant association between homozygosity for the mutant allele of this polymorphism and lack of response to infliximab was seen in the exploratory cohort. Haplotype analysis did not further increase the strength or significance of this association.
The association between the polymorphism in exon 6 of the TNF-receptor II in the exploratory cohort was not replicated in the larger, confirmatory study population. Although the odds ratio (OR) for non-response in homozygote mutants in the first cohort was estimated to be 8.5, it entailed a wide 95% confidence interval ranging from 0.9-206.3 (due to low polymorphism frequency). The power of the replication cohort is higher than 99% to detect an effect corresponding to an odds ratio of 8.5. However, the power is only 56% to re-detect an effect with an OR of 2. The 95% confidence interval of the odds ratio as estimated from the confirmatory cohort was 0.2-1.7. Therefore, the association 
finding in the exploratory cohort is either a false positive or points towards a weak risk factor. Another explanation for the discrepancy could be the influence of population differences between the trials. There were slight differences between study designs. The exploratory cohort included only steroid refractory, chronic active patients but allowed for patients with fistulizing disease. In contrast, the second trial also allowed the inclusion of active patients with Crohn's disease with little pre-treatment (ie only 5-aminosalicylates) but excluded patients with draining fistula. Nevertheless, most patients included in the second trial had refractory disease (62% of patients received glucocorticoids and 79% immunosuppressives (azathioprine, 6-mercaptopurine, methotrexate)). Response rates of patients, who received only 5-aminosalicylates, were not different from the rest of the trial population.
It should be also pointed out that the clinical endpoint was defined 4 weeks after the first infusion of infliximab in the first trial, whereas clinical assessment was performed after 2 weeks in the second trial. The same activity related parameters to qualify disease activity were used. It appears that almost all of the clinical responses to infliximab in Crohn's disease are achieved early within the first 10-14 days. There were also small differences in ethnic compositions between the studies analysed with all patients being Caucasian in the first cohort, in comparison with 95.8% being classified as Caucasian in the second trial (2.1% Black, www.nature.com/tpj 0.9% Asian and 1.2% others). Although no influence of race on response rates was seen, even small inhomogeneities within the Caucasian population (homogenous German vs an international population) may contribute to the different association results.
While a role of this TNF-receptor II polymorphism in the response to infliximab, as discussed above, can therefore not be completely ruled out, it appears unlikely that the exon 6 polymorphism would be a useful diagnostic marker. The novel polymorphism detected in exon 2 of the TNF-R II gene follows the same association pattern as exon 6 polymorphism due to strong linkage disequilibrium between the two polymorphisms. The discrepancy noted between the two samples in our study may also serve to emphasize the general necessity for very large cohorts and a verification design (eg use of two independent and sufficiently large cohorts) in pharmacogenetic studies.
None of the non-coding polymorphisms in the TNFreceptors I and II genes showed any association with treatment response in the exploratory cohort. These negative findings were confirmed through the analysis of the confirmatory sample. Since the combined power of the twocohort design is very high as discussed above, these polymorphisms can be therefore effectively excluded from representing useful pharmacogenetic markers for the response to infliximab in Crohn's disease.
In a recent study, mutations in the lymphotoxin-A (LTA) gene were reported to have predictive value for a therapeutic response to infliximab in Crohn's disease. 42 Homozygote patients with the LTA haplotype 1-1-1-1 did not respond to treatment with infliximab in an analysis of 59 patients from a clinical trial in active Crohn's disease 7 and presence of pANCA was associated with a reduced reponse. Three LTA haplotypes were present (1-1-1-1, 2-1-1-2 and 1-2-2-1) . Certain TNF-microsatellite haplotypes were in linkage disequilibrium with the 1-1-1-1 haplotype. The frequency of homozygotes for the LTA haplotype 1-1-1-1 was 13 %.
Several polymorphisms in the TNF-␣ promoter are associated with an increased in vitro secretion of TNF. 25, 26, [39] [40] [41] An altered TNF promoter leading to high levels of TNF secretion would represent a plausible pathophysiological hypothesis for a non-response to anti-TNF therapy with infliximab. 25, 43 Recently, Vermeire and co-workers described an association between the TNF Ϫ308 polymorphism and response to infliximab in a Belgian population of Crohn's disease patients. 44 In contrast, our study failed to show associations between outcome of therapy and any of the single nucleotide polymorphisms in the promoter of the TNF-␣ gene (P Ͼ 0.5). The confirmation in the second cohort can be regarded as reliable statistical proof of exclusion as major factors.
The two-cohort design is also suitable to explore the role of polymorphisms as risk factors for Crohn's disease in general, as all of the investigated genes are located in chromosomal regions implicated in linkage studies for Crohn's disease (Table 5) . Association between the mutated allele of TNF-receptor II exon 6 and susceptibility to several autoimmune diseases has been reported previously, including systemic lupus erythematosus 47 and rheumatoid arthritis 48 in the Japanese population, but may be less relevant in the Spanish and UK population of Lupus patients. 49 Mice with a functionally silent TNF-receptor II gene develop a higher rate of autoimmune conditions. 50, 51 The comparison between the allele and genotype frequencies of the TNF receptor II, TNF-R I and TNF variations between the 534 sporadic chronic active Crohn's disease patients in the two cohorts and the 370 unrelated healthy controls did not show any association with the diagnosis (P Ͼ 0.5). The independent negative findings in both cohorts indicate that the polymorphisms investigated in this study can be ruled out as major genetic contributors to the risk for Crohn's disease. However, a bias in population stratification may obscure weak associations. The healthy blood donor population, which was examined as a comparative group, will reflect a TNF-R II 1p36 yes 21, 45, 46 The Pharmacogenomics Journal different selection pressure than the international study population of the second trial and even the German population of the first trial. The immunology of non-response to infliximab is characterized by a persistent activation of the NFB system and a rebound of TNF production. 34 Future pharmacogenetic studies will therefore have to investigate additional genes downstream of the TNF receptor signal transduction (eg TRAF and the nuclear factor kappa B system). In addition, genes involved in the regulation of TNF appear to be suitable candidates to study the genetic background of the response to infliximab in Crohn's disease.
The results of this study demonstrate the need for a twostage design of pharmacogenetic studies, especially if relatively rare variants are implicated in the treatment response. Even small P values (ie P ϭ 0.01 in the exploratory cohort) may lead to false conclusions. As prospective trials in which study participants are stratified by genotyping are needed before admitting pharmacogenetic tests into clinical practice, a two-cohort design provides an effective way to focus resources on relevant hypotheses.
